Latest concepts in frontline therapy for paediatric ALL
Latest concepts in frontline therapy for paediatric ALL
Dasatinib vs imatinib in the treatment of paediatric ALL
Lenalidomide maintenance for transplant eligible and transplant ineligible newly diagnosed myeloma patients
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?
Targeting CD70 with cusatuzumab eliminates acute myeloid leukaemia stem cells in humans
Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis
Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo
Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer
SABCS 2019 highlights
The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL